Parameters for the seven ODE models. by Hope Murphy (8843516)

IC₅₀ (left) and <i>ε</i>_max (right) measurement time dependence for all seven models. by Hope Murphy (8843516)

Example of the process used to determine time dependence of <i>ε</i>_max and IC₅₀. by Hope Murphy (8843516)

No change in muscle size and force, but a decrease in TB mass in 1-mo Lmna^HSA-cko mice. by Lei Xiong (334812)

Depletion of NUP proteins decreases MLV infection of DCs but not NIH3T3 cells. by Karen Salas-Briceno (10934215)

The inhibitory activity of the most active compounds against Glo-I enzyme with less than 50 µM. Their supportive corresponding docking values on two different protocols are display... by MohammedBashar Al-Qazzan (22439236)

Elementary Steps in Olefin Metathesis: Nickelacyclobutanes via Cycloaddition to Nickel Carbenes by Samantha K. Cormier (16872384)

“…This is the sole example to date of an obervable NiCB generated via cycloaddition, beyond the fluorinated examples. Computations pinpoint a decreased energy barrier to cycloreversion, relative to reductive elimination or β-H elimination, as the core requirement to achieve metathesis. …”

Data_Sheet_1_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx by Nicholas Reyes (16390233)

“…Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”

Data_Sheet_2_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx by Nicholas Reyes (16390233)

“…Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”

Data_Sheet_1_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx by Nicholas Reyes (16390233)

“…Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”

Data_Sheet_2_Botulinum toxin A decreases neural activity in pain-related brain regions in individuals with chronic ocular pain and photophobia.docx by Nicholas Reyes (16390233)

“…Four to six weeks after BoNT-A injection, unpleasantness scores decreased (48.1 ± 33.6), but the change was not significant. …”

SIINFEKL-specific CD8⁺ T cells treated with anti-CXCR3 decreased the polyfunctionality. by Camila Pontes Ferreira (6194006)

Phenotypic delay decreases the probability of a bacterial infection surviving antibiotic treatment. by Martín Carballo-Pacheco (8911910)

Effects of GJE extract treatment decreased accumulation of Col1a1. by Natnicha Suttawong (22367172)

Kinetic Insights into Ammonia Decomposition over Rhodium: A Combined Experimental, Modeling, and Theoretical Study by Fanggang Zhang (22312742)

“…The results demonstrated that reaction rates initially increased with pressure but subsequently exhibited a slight decrease at higher pressures. A thermodynamically consistent microkinetic model consisting of 12 elementary steps was developed, incorporating pressure-dependent adsorption behavior of ammonia. …”

Nicotine decreased Akt phosphorylation in SK-BR-3 cells. by Masanori A. Murayama (5774585)

mTORC1 hyperactivation led to a decreased autophagic activity in the podocytes. by Wakiko Iwata (8600457)

“…<p>(<b>A</b>) Primary cultured podocytes were isolated from <i>Tsc2</i>^{Δ<i>podocyte</i>} and wild-type controls, followed by western blot analyses of TSC2, phospho-4EBP1, LC3B type II, p62, phospho-ULK1, and β-tubulin. …”

Juvenile demyelination leads to a decrease in axonal complexity of PFC PV interneurons. by Sara Hijazi (21656615)

“…<b>F</b>. Example image of a biocytin-labeled PFC PV interneuron from a control mouse (left) and from cuprizone-treated mouse (right); scale bar: 50 µm. …”

Process steps in the Entscheidungsnavi. by Christian Hannes (17817132)

STEP in-person sessions. by Shirley Yen (12632685)

“…Results from a pilot RCT demonstrated engagement of the target (positive affect) and a decrease in clinical outcomes (suicidal events; i.e., either a suicide attempt or an emergency intervention for an acute suicidal crisis), providing support to test the clinical effectiveness of STEP in a larger clinical trial with clinical staff implementing the intervention.…”